293 related articles for article (PubMed ID: 31154396)
1. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression.
Wang D; Li X; Li J; Lu Y; Zhao S; Tang X; Chen X; Li J; Zheng Y; Li S; Sun R; Yan M; Yu D; Cao G; Yang Y
Gut; 2019 Oct; 68(10):1846-1857. PubMed ID: 31154396
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity.
Ma W; Ho DW; Sze KM; Tsui YM; Chan LK; Lee JM; Ng IO
Mol Carcinog; 2019 May; 58(5):643-653. PubMed ID: 30575099
[TBL] [Abstract][Full Text] [Related]
3. Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells.
Maruyama W; Shirakawa K; Matsui H; Matsumoto T; Yamazaki H; Sarca AD; Kazuma Y; Kobayashi M; Shindo K; Takaori-Kondo A
Biochem Biophys Res Commun; 2016 Sep; 478(3):1466-71. PubMed ID: 27577680
[TBL] [Abstract][Full Text] [Related]
4. Human Papillomavirus 16 E6 Upregulates APOBEC3B via the TEAD Transcription Factor.
Mori S; Takeuchi T; Ishii Y; Yugawa T; Kiyono T; Nishina H; Kukimoto I
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077648
[TBL] [Abstract][Full Text] [Related]
5. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
[TBL] [Abstract][Full Text] [Related]
6. Genetic Polymorphisms Predisposing the Interleukin 6-Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations.
Liu W; Wu J; Yang F; Ma L; Ni C; Hou X; Wang L; Xu A; Song J; Deng Y; Xian L; Li Z; Wang S; Chen X; Yin J; Han X; Li C; Zhao J; Cao G
Clin Cancer Res; 2019 Sep; 25(18):5525-5536. PubMed ID: 31152021
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3B and IL-6 form a positive feedback loop in hepatocellular carcinoma cells.
Li S; Bao X; Wang D; You L; Li X; Yang H; Bian J; Wang Y; Yang Y
Sci China Life Sci; 2017 Jun; 60(6):617-626. PubMed ID: 28646470
[TBL] [Abstract][Full Text] [Related]
8. Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB.
Periyasamy M; Singh AK; Gemma C; Farzan R; Allsopp RC; Shaw JA; Charmsaz S; Young LS; Cunnea P; Coombes RC; Győrffy B; Buluwela L; Ali S
Oncogene; 2021 Feb; 40(6):1077-1090. PubMed ID: 33323971
[TBL] [Abstract][Full Text] [Related]
9. Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages.
Yan W; Liu X; Ma H; Zhang H; Song X; Gao L; Liang X; Ma C
Gut; 2015 Oct; 64(10):1593-604. PubMed ID: 25608525
[TBL] [Abstract][Full Text] [Related]
10. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
[TBL] [Abstract][Full Text] [Related]
11. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
Periyasamy M; Singh AK; Gemma C; Kranjec C; Farzan R; Leach DA; Navaratnam N; Pálinkás HL; Vértessy BG; Fenton TR; Doorbar J; Fuller-Pace F; Meek DW; Coombes RC; Buluwela L; Ali S
Nucleic Acids Res; 2017 Nov; 45(19):11056-11069. PubMed ID: 28977491
[TBL] [Abstract][Full Text] [Related]
12. B-Myb Induces APOBEC3B Expression Leading to Somatic Mutation in Multiple Cancers.
Chou WC; Chen WT; Hsiung CN; Hu LY; Yu JC; Hsu HM; Shen CY
Sci Rep; 2017 Mar; 7():44089. PubMed ID: 28276478
[TBL] [Abstract][Full Text] [Related]
13. Identification of APOBEC3B promoter elements responsible for activation by human papillomavirus type 16 E6.
Mori S; Takeuchi T; Ishii Y; Kukimoto I
Biochem Biophys Res Commun; 2015 May; 460(3):555-60. PubMed ID: 25800874
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
Tsuboi M; Yamane A; Horiguchi J; Yokobori T; Kawabata-Iwakawa R; Yoshiyama S; Rokudai S; Odawara H; Tokiniwa H; Oyama T; Takeyoshi I; Nishiyama M
Breast Cancer; 2016 Sep; 23(5):780-8. PubMed ID: 26476745
[TBL] [Abstract][Full Text] [Related]
15. APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.
Yamazaki H; Shirakawa K; Matsumoto T; Kazuma Y; Matsui H; Horisawa Y; Stanford E; Sarca AD; Shirakawa R; Shindo K; Takaori-Kondo A
PLoS One; 2020; 15(1):e0223463. PubMed ID: 31914134
[TBL] [Abstract][Full Text] [Related]
16. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Caswell DR; Gui P; Mayekar MK; Law EK; Pich O; Bailey C; Boumelha J; Kerr DL; Blakely CM; Manabe T; Martinez-Ruiz C; Bakker B; De Dios Palomino Villcas J; I Vokes N; Dietzen M; Angelova M; Gini B; Tamaki W; Allegakoen P; Wu W; Humpton TJ; Hill W; Tomaschko M; Lu WT; Haderk F; Al Bakir M; Nagano A; Gimeno-Valiente F; de Carné Trécesson S; Vendramin R; Barbè V; Mugabo M; Weeden CE; Rowan A; McCoach CE; Almeida B; Green M; Gomez C; Nanjo S; Barbosa D; Moore C; Przewrocka J; Black JRM; Grönroos E; Suarez-Bonnet A; Priestnall SL; Zverev C; Lighterness S; Cormack J; Olivas V; Cech L; Andrews T; Rule B; Jiao Y; Zhang X; Ashford P; Durfee C; Venkatesan S; Temiz NA; Tan L; Larson LK; Argyris PP; Brown WL; Yu EA; Rotow JK; Guha U; Roper N; Yu J; Vogel RI; Thomas NJ; Marra A; Selenica P; Yu H; Bakhoum SF; Chew SK; Reis-Filho JS; Jamal-Hanjani M; Vousden KH; McGranahan N; Van Allen EM; Kanu N; Harris RS; Downward J; Bivona TG; Swanton C
Nat Genet; 2024 Jan; 56(1):60-73. PubMed ID: 38049664
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.
Cescon DW; Haibe-Kains B; Mak TW
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2841-6. PubMed ID: 25730878
[TBL] [Abstract][Full Text] [Related]
18. APOBEC3B is preferentially expressed at the G2/M phase of cell cycle.
Hirabayashi S; Shirakawa K; Horisawa Y; Matsumoto T; Matsui H; Yamazaki H; Sarca AD; Kazuma Y; Nomura R; Konishi Y; Takeuchi S; Stanford E; Kawaji H; Murakawa Y; Takaori-Kondo A
Biochem Biophys Res Commun; 2021 Mar; 546():178-184. PubMed ID: 33592502
[TBL] [Abstract][Full Text] [Related]
19. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
20. Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B.
Akre MK; Starrett GJ; Quist JS; Temiz NA; Carpenter MA; Tutt AN; Grigoriadis A; Harris RS
PLoS One; 2016; 11(5):e0155391. PubMed ID: 27163364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
